Company Overview of Universität Ulm
University of Ulm is an educational institution.
Key Executives for Universität Ulm
Universität Ulm does not have any Key Executives recorded.
Universität Ulm Key Developments
Theralase Technologies Inc. Partners with the University of Ulm
Nov 12 15
Theralase Technologies Inc. announced that it has partnered with the University of Ulm (‘Ulm’) to investigate the localization of its lead Photo Dynamic Compound (‘PDC’) within cancer cells and shine more proverbial light on the Mechanism of Action (‘MOA’) on how this PDC is so effective in the destruction of cancer cells when laser light activated. The scope of the current project between Ulm and Theralase is to investigate the localization (where do they locate in the cell) and the MOA (how they work on the cell) of Theralase's lead PDC, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer (‘NMIBC’). The head of the core facility "Confocal and Multiphoton Microscopy", located in the Medical Faculty of Ulm, is Dr. Angelika Rueck, who will be conducting the research. The heart of the facility consists of two laser-scanning microscopes capable of live cell imaging through detailed Fluorescence Lifetime Imaging Microscopy (‘FLIM’) and Phosphorescence Lifetime Imaging Microscopy (‘PLIM’). Under the current research agreement, Dr. Rueck will determine the localization and MOA of TLD-1433 through the following phases: Phase 1 - Intracellular localization of TLD-1433 and cytotoxicity (cell kill) will be investigated in two (2) different urothelial carcinoma tumour cell lines (HT1376 and T24) and one (1) normal human urothelial cell line as a function of time. Phase 2 - FLIM and PLIM will be completed to more fully understand how TLD-1433 affects cancer cell metabolism and to identify the MOA of mediated cell death by this PDC. Phase 3 - Cell metabolism in the three cell lines, in the presence and not of TLD-1433 will be analyzed.
Hydrogenics Joins German H2FLY Consortium to Enable Zero-Emission Passenger Flights Using Fuel Cell Technology
Oct 15 15
Hydrogenics Corporation announced that it has joined with a consortium of companies to develop the zero-emission four-seater passenger plane. The announcement was made at the International Trade Fair World of Energy Solutions in Stuttgart, Germany on October 12, 2015. Hydrogenics joins with partners; the DLR Institute of Technical Thermodynamics, the University of Ulm, aircraft manufacturer Pipistrel, and the airport of Stuttgart in the consortium named H2FLY. The consortium's vision is the advancement of emission-free electrified flight with hydrogen. The aircraft, named HY4, will make its maiden flights from its home base at the Stuttgart Airport in the summer of 2016.
FEI Enters into an Agreement with University of Ulm and CEOS GmbH to Develop a Sub-Angström Low-Voltage Electron Microscope
Mar 16 15
FEI announced that it has entered into an agreement with Germany's University of Ulm and Heidelberg-based CEOS GmbH to develop a sub-?ngström low-voltage electron microscope, in the frame of Uni-Ulm's SALVE project. The multi-year collaboration will involve the planned development of a dedicated aberration-corrected transmission electron microscope (TEM) that is capable of imaging radiation-sensitive materials, such as two-dimensional (2D) and organic samples, and selected molecules, with molecular or even atomic-scale resolution. The TEM is also expected to provide spectroscopic information at very low acceleration voltages.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries